Bristol-Myers Squibb Company (BMY)

Check out top investors' recommendation for BMY
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
61.29
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
63%/38%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Its principal products include Plavix for protection against fatal or non-fatal heart attack or stroke; Avapro/Avalide for the treatment of hypertension and diabetic nephropathy; Eliquis to prevent and treat venous thromboembolic disorders and stroke prevention in atrial fibrillation; Abilify, an agent for adult patients with schizophrenia, bipolar mania disorder, and depressive disorder; and Reyataz and Sustiva to treat human immunodeficiency virus. The company’s products also include Baraclude, an inhibitor of hepatitis B virus; Erbitux to target and block the epidermal growth factor receptor; Sprycel for treatment of chronic myeloid leukemia in adults; Yervoy to treat metastatic melanoma; Orencia to treat adult patients with moderate to severe rheumatoid arthritis; Nulojix to prevent kidney transplant rejection; Onglyza/Kombiglyze, Byetta, and Bydureon to treat type 2 diabetes; and Forxiga for the treatment of diabetes. Its products under Phase III clinical trials include Asunaprevir and Daclatasvir, which are oral small molecule to treat hepatitis C virus infection; Peginterferon lambda, a novel type 3 interferon for hepatitis C virus infection; Elotuzumab for multiple myeloma; and Nivolumab, an anticancer treatment, as well as products under the registrational process comprises Metreleptin for the treatment of lipodystrophy. The company sells its products to wholesalers, as well as directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Sector:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Alex Arfaei BMO Capital Markets Sell   Nov 13, '17     49.00  Nov 13, '18  N/A 
John Boris Citi Buy   Oct 30, '17       Oct 30, '18  N/A 
Seamus Fernandez Leerink Swann Llc Buy   Oct 23, '17     72.00  Oct 23, '18  N/A 
Andrew Baum Citi Buy   Oct 18, '17     72.00  Oct 18, '18  N/A 
Alex Arfaei BMO Capital Markets Sell   Oct 12, '17     49.00  Oct 12, '18  N/A 
Marc Goodman UBS Buy   Oct 06, '17     72.00  Oct 06, '18  N/A 
Alex Arfaei BMO Capital Markets Sell   Sep 07, '17     49.00  Sep 07, '18  N/A 
Jeffrey Holford Jefferies & Co. Buy   Aug 23, '17     66.00  Aug 23, '18  N/A 
Seamus Fernandez Leerink Swann Llc Buy   Jul 27, '17       Jul 27, '18  N/A 
Alex Arfaei BMO Capital Markets Sell   Jul 23, '17     47.00  Jul 23, '18  N/A 
David Steinberg Deutsche Bank Securities Buy   Jul 17, '17     63.00  Jul 17, '18  N/A 
Andy Barish Jefferies & Co. Buy   May 24, '17     64.00  May 24, '18  N/A 
Chris Schott JPMorgan Buy   May 11, '17       May 11, '18  N/A 
Alex Arfaei BMO Capital Markets Sell   May 03, '17     47.00  May 03, '18  N/A 
John Eade Argus Research Company Buy   Feb 22, '17     75.00  Feb 22, '18  N/A 
Seamus Fernandez Leerink Swann Llc Buy   Jan 27, '17       Jan 27, '18  N/A 
Chris Schott JPMorgan Buy   Jan 20, '17       Jan 20, '18  N/A 
Jeffrey Holford Jefferies & Co. Buy   Jan 20, '17       Jan 20, '18  N/A 
Gerardo Torculas Unaffiliated Buy   Jan 12, '17   56.22  60.00  Feb 12, '17  -8.13% 
Jeffrey Holford Jefferies & Co. Buy   Dec 19, '16       Dec 19, '17  N/A 
< previous1234